-
Bestatin Inhibition of Leucine Aminopeptidase
2026-09-15
The reference study used high-resolution X-ray crystallography to show how Bestatin occupies the active site of bovine lens leucine aminopeptidase and coordinates a catalytically relevant zinc ion. Its transition-state-like binding model connects inhibitor recognition with a proposed mechanism for peptide hydrolysis, providing a structural basis for interpreting aminopeptidase inhibition experiments.
-
HNRNPU K181 Lactylation Reprograms Cervical Cancer
2026-09-15
This Advanced Science study identifies HNRNPU K181 lactylation as a lactate-responsive mechanism that stabilizes HNRNPU, promotes PHGDH expression, and redirects serine metabolism in cervical cancer. Its integrated molecular, metabolic, and in vivo evidence provides a framework for testing how non-histone modification controls RNA processing and tumor growth.
-
Toremifene in Prostate Cancer Research
2026-09-14
Toremifene offers a practical SERM-based framework for testing hormone-responsive cancer biology alongside metastasis-associated calcium signaling. This workflow connects concentration-controlled cell growth assays with STIM1/TSPAN18 mechanistic readouts while clearly separating established evidence from testable research hypotheses.
-
EZ Cap™ Firefly Luciferase mRNA: Assay Design
2026-09-14
Discover how EZ Cap™ Firefly Luciferase mRNA can function as more than a reporter by separating delivery, endosomal release, and translation in RNA experiments. This guide combines molecular design, assay controls, handling parameters, and mechanistic insights from recent nanoparticle research.
-
How Drug Response Metrics Improve Cancer Assays
2026-09-13
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of anticancer drug response. The framework supports better time-resolved assay design, more cautious interpretation of viability data, and clearer translation between cytostatic and cytotoxic effects.
-
AmpliFold Capture-and-Release for Sensitive LFAs
2026-09-12
The reference study introduces AmpliFold, a capture-and-release strategy that addresses the fast-binding constraints of lateral flow assays by temporarily sequestering analyte complexes and enabling high-affinity rebinding. In a HER2 model, the approach improved detection performance by up to 16-fold and retained sensitivity gains with large gold nanoparticles and human-serum samples.
-
FPH1 (BRD-6125) Hepatocyte Workflow Guide
2026-09-12
FPH1 (BRD-6125) supports functional expansion of primary human hepatocytes while preserving decision-relevant readouts such as albumin, CYP3A4, and AFP. This practical guide connects controlled proliferation assays with iPS-derived hepatocyte workflows and explains how a light-regulated translation study can inform, but not replace, hepatocyte assay design.
-
SB-505124 Hydrochloride and Cell Mechanics
2026-09-11
A translational perspective on using SB-505124 hydrochloride to dissect ALK4/5/7 signaling, fibroblast activation, and the mechanobiology questions raised by the MRTFA-KCNMB1 axis in cancer.
-
D-N-Acetylgalactosamine Workflow and QC Guide
2026-09-11
D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein, brain heteropolysaccharide, and glycosylation-related workflows. It is suitable for aqueous or compatible DMSO preparations, but it should not be used in ethanol-based methods or retained as a long-term solution.
-
α-Bungarotoxin: Reliable Nicotinic Receptor Blockade
2026-09-10
This scenario-driven guide shows how α-Bungarotoxin (SKU B6950) can strengthen mechanistic interpretation in viability, proliferation, cytotoxicity, and cholinergic signaling assays. It links receptor pharmacology with practical design, storage, optimization, vendor evaluation, and evidence from a 2026 placental necroptosis study.
-
GANT61 Workflows for GLI-Driven Cancer Research
2026-09-10
GANT61 is a practical GLI inhibitor for separating Hedgehog-pathway dependence from nonspecific cytotoxicity in cell, co-culture, and xenograft studies. This workflow-focused guide covers solvent handling, dose-response design, immune-evasion assays, and troubleshooting for more reproducible cancer research.
-
HyperScribe T7 High Yield Cy3 RNA Labeling Kit
2026-09-09
Build fluorescent RNA probes for in situ hybridization and Northern blot workflows while balancing transcription yield against Cy3 signal density. The HyperScribe T7 High Yield Cy3 RNA Labeling Kit also supports assay development around RNA localization, probe specificity, and delivery-oriented research.
-
Syringin Natural Product for RCC Assay Design
2026-09-09
Build a practical renal cell carcinoma workflow around Syringin, combining viability, migration, apoptosis, and EGFR/PI3K/Akt measurements with sunitinib-sensitization studies. The guide emphasizes compound handling, orthogonal validation, dose-matrix design, and troubleshooting so natural product research produces interpretable mechanistic data.
-
Rational Design of NIR-II Liposomes for Intravital Imaging
2026-09-08
Yu and colleagues developed an IR-1061 liposomal nanosystem by systematically examining phospholipid charge and fluorophore loading. Their results show that anionic liposomes improve encapsulation, whereas excessive IR-1061 promotes aggregation and weakens fluorescence, enabling a formulation with high vascular contrast and persistent imaging over more than 16 hours in mice.
-
BIBR 1532 Telomerase Inhibitor Workflows
2026-09-08
Build a time-resolved telomerase inhibition workflow with BIBR 1532, linking hTERT suppression to proliferation, apoptosis, and telomere phenotypes. The guide also shows how to adapt findings from CF10–EdU research without confusing DNA damage with direct telomerase inhibition.